表紙
市場調查報告書
商品編碼
971975

阻塞性睡眠呼吸(OSA)市場:見解,流行病學和2030年預測

Obstructive Sleep Apnea Market Insights, Epidemiology, and Market Forecast - 2030

出版日期: 按訂單生產 | 出版商: DelveInsight Business Research LLP | 英文 166 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

七個主要國家(美國,德國,法國,意大利,西班牙和日本)的阻塞性睡眠呼吸(OSA)市場規模預計將以顯著的複合年增長率增長。美國是最大的市場規模,2017年達到1.653億美元。同年,日本市場的規模為1510萬美元。

此外,2017年在7個國家/地區診斷出的病例數為283,026,其中美國為169,439,日本為33,406。

本報告研究了七個主要國家(美國,德國,法國,意大利,西班牙和日本)的阻塞性睡眠呼吸(OSA)市場,包括市場規模和預測,當前的治療方法和新的它提供有關各種方法,市場增長因素和障礙,機會,未滿足的需求,案例研究等的信息。

目錄

第1章重要見識

第2章執行摘要

第3章OSA SWOT分析

第4章市場概述

  • 2017年市場佔有率
  • 2030年的市場佔有率

第5章疾病的背景和概述

  • 簡介
  • 病因
  • 基於嚴重度的分類
  • 臨床症狀
  • 症狀
  • 病理生理學
  • 危險因素
  • 診斷

第6章流行病學和患者人群

  • 主要發現

第7章主要國家的流行病學

  • 先決條件和理由
  • 7個主要國家的總診斷患病率
  • 美國
  • 德國
  • 法國
  • 意大利
  • 西班牙
  • 英國
  • 日本

第8章治療

第9章未滿足的需求

第10章組織對OSA的貢獻

第11章案例研究

  • 案例研究:自然睡眠期間患者的抽吸結束圖像
  • 解決上肢氣道刺激治療阻塞性睡眠呼吸暫停綜合症併發症所致的下肢發癢症狀
  • 案例研究:尖端巨大疾病導致的阻塞性睡眠呼吸暫停
  • 案例研究:2型糖尿病(男性)的睡眠誤診診斷改善控制

第12章患者旅程

第13章KOL的觀點

第14章非處方治療

  • Provigil: Teva Pharmaceuticals
    • 產品概述
    • 其他發展活動
    • 臨床發展
    • 安全性和有效性
  • Nuvigil:Teva Pharmaceuticals
  • Solriamfetol:Jazz Pharmaceuticals
    • 其他發展活動

第15章新療法

  • Daridorexant:Idorsia Pharmaceuticals
    • 產品說明
    • 其他發展活動
    • 臨床發展
  • BAY2586116: Bayer
  • AD036:Apnimed
  • AD128:Apnimed

第7章主要國家的市場分析

  • 主要發現
  • 7個主要國家/地區的市場規模

第17章對7個主要國家/地區的市場前景

  • 美國市場規模
  • 德國
  • 法國
  • 意大利
  • 西班牙
  • 英國
  • 日本

第18章市場增長因素

第19章市場壁壘

第20章贖回

第21章附錄

  • 報告研究方法
  • 參考

第22章Delve Insight Services

第23章免責聲明

第24章關於Delve Insight

目錄
Product Code: DIMI0372

DelveInsight's 'Obstructive Sleep Apnea Market Insights, Epidemiology, and Market Forecast - 2030' report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Obstructive Sleep Apnea in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Obstructive Sleep Apnea market report provides analysis regarding current treatment practices, emerging drug-like AD036 and AD128 (Apnimed) and BAY2586116 (Bayer's) potential therapies, market share of the individual therapies, historical, current, and forecasted Obstructive Sleep Apnea market size from 2017 to 2030 segmented by seven major markets.

The report also covers current Obstructive Sleep Apnea treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the market's underlying potential.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Obstructive Sleep Apnea - Disease Understanding and Treatment Algorithm

Obstructive Sleep Apnea Overview

Obstructive Sleep Apnea (OSA) is a sleep-related breathing disorder that involves a decrease or complete halt in airflow despite an ongoing effort to breathe. It occurs when the muscles relax during sleep, causing soft tissue in the back of the throat to collapse and block the upper airway. Obstructive Sleep Apnea (OSA) may manifest in several ways, from subtle intrusion into daily life to profound sleepiness, snoring, witnessed Apneas, and other symptoms.

The diagnosis of Obstructive Sleep Apnea (OSA) requires the combined assessment of relevant clinical features and the objective demonstration of abnormal breathing during sleep. Current evidence indicates that attempts to base the clinical syndrome diagnosis on either aspect alone are unreliable. The ''gold standard'' for the diagnosis of OSAS is full polysomnography, which provides detailed information on sleep state, respiratory and gas exchange abnormalities, in addition to a range of other variables including body position, heart rate and rhythm, and muscle tone and contraction.

Obstructive Sleep Apnea Treatment

This chapter covers the details of conventional and current medical therapies available in the Obstructive Sleep Apnea market to treat the condition. It also provides the country-wise Obstructive Sleep Apnea treatment guidelines across the United States, Europe, and Japan.

DelveInsight's Obstructive Sleep Apnea market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Obstructive Sleep Apnea treatment algorithms and treatment guidelines in the US, Europe, and Japan.

The current treatment landscape of OSA mainly comprises options including continuous positive airway pressure (CPAP), oral appliances therapy, surgery, and lifestyle changes such as weight loss or body positioning during sleep. Among all these, CPAP is the standard gold treatment for OSA and occupies the largest market share (devices). However, PAP remains the most preferred mode of treating OSA, as per expert opinions, despite this, about 10% of the patients experience excessive daytime sleepiness. To combat this, these patients are further treated with wakefulness promoters [Modafinil, Armodafinil, and solriamfetol].

Obstructive Sleep Apnea Epidemiology

The Obstructive Sleep Apnea epidemiology chapters provide insights about historical and current Obstructive Sleep Apnea patient pool and forecasted trends for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Obstructive Sleep Apnea epidemiology is segmented by Total diagnosed prevalent cases of OSA, Gender-specific cases of Obstructive Sleep Apnea, Age-specific cases of Obstructive Sleep Apnea, Severity-specific cases of OSA. The report includes a thorough analysis of all segmentations.

According to DelveInsight's estimate, the total diagnosed prevalent cases of Obstructive Sleep Apnea in 7MM countries were found to be 283,026 cases in 2017. Among all the seven major markets, the United States accounts for the highest number of Obstructive Sleep Apnea cases.

In the US, the diagnosed prevalence of Obstructive Sleep Apnea was 169,439 cases in 2017, whereas Japan had 33,406 cases of Obstructive Sleep Apnea in 2017.

Obstructive Sleep Apnea Drug Chapters

The drug chapter segment of the Obstructive Sleep Apnea report encloses a detailed analysis of the Obstructive Sleep Apnea pipeline drug. It also helps understand the Obstructive Sleep Apnea clinical trial details, expressive pharmacological action, the included drug's agreements, and the latest news and press releases.

To date, few drugs have been developed which address the underlying cause of OSA, and since the entire landscape is devoid of any effective pharmaceutical treatment option, any significant development in this direction is expected to create a tectonic impact on the existing market scenario during our forecast period.

Obstructive Sleep Apnea Market Outlook

The Obstructive Sleep Apnea market size is expected to increase at a significant CAGR during the study period (2017-2030). Among all the seven major markets, the United States accounted for the largest Obstructive Sleep Apnea market size, with USD 165.3 million in 2017. Japan's market size of Obstructive Sleep Apnea was USD 15.1 million in the same year.

Obstructive Sleep Apnea Drugs Uptake

This section focuses on the rate of uptake of the potential drugs in the Obstructive Sleep Apnea market that are expected to get launched in the market during the study period 2017-2030. The analysis covers Obstructive Sleep Apnea market uptake by drugs, patient uptake by therapies, and sale of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and comparison of the drugs based on market share and size, which will again be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of the Obstructive Sleep Apnea market is anticipated to experience a positive shift in the coming years owing to the expected launch of emerging therapies.

Obstructive Sleep Apnea Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Obstructive Sleep Apnea key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of Obstructive Sleep Apnea collaborations, acquisition, and merger, licensing patent details, and other information for Obstructive Sleep Apnea emerging therapies.

Reimbursement Scenario in Obstructive Sleep Apnea

Approaching reimbursement, proactively, can positively impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL Views

To keep up with current market trends, we take KOLs and SME's opinion working in the Obstructive Sleep Apnea domain through primary research to fill the data gaps and validate our secondary research. This will support the clients in potential upcoming novel treatment by identifying the market's overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Obstructive Sleep Apnea Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, and Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Report Highlights:

  • In the coming years, the Obstructive Sleep Apnea market scenario is expected to alter across the 7MM due to the launch of a better therapy covering the drawbacks of the standard of care.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Obstructive Sleep Apnea Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Obstructive Sleep Apnea Pipeline Analysis
  • Obstructive Sleep Apnea Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Obstructive Sleep Apnea Report Key Strengths

  • 11 years Forecast
  • 7MM Coverage
  • Obstructive Sleep Apnea Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Obstructive Sleep Apnea Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Obstructive Sleep Apnea market share (%) distribution in 2017, and how it would look in 2030?
  • What would be the Obstructive Sleep Apnea total market size and market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM, and which country will have the largest Obstructive Sleep Apnea market size during the forecast period (2017-2030)?
  • At what CAGR, the Obstructive Sleep Apnea market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Obstructive Sleep Apnea market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Obstructive Sleep Apnea market growth till 2030, and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risks, burdens, and unmet needs of obstructive sleep apnea?
  • What is the historical obstructive sleep apnea patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of obstructive sleep apnea in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to obstructive sleep apnea?
  • Out of all 7MM countries, which country would have the highest prevalent obstructive sleep apnea population during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the obstructive sleep apnea treatment, along with the approved therapy?
  • What are the current treatment guidelines for treating obstructive sleep apnea in the USA, Europe, and Japan?
  • What is the obstructive sleep apnea marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of obstructive sleep apnea?
  • How many therapies are developed by each company for obstructive sleep apnea treatment?
  • How many are emerging therapies in mid-stage and late-stage of development for obstructive sleep apnea treatment?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to obstructive sleep apnea therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for obstructive sleep apnea and their status?
  • What are the key designations that have been granted for the emerging therapies for obstructive sleep apnea?
  • What are the global historical and forecasted market of obstructive sleep apnea?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the obstructive sleep apnea market
  • To understand the future market competition in the obstructive sleep apnea market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for obstructive sleep apnea in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for obstructive sleep apnea market
  • To understand the future market competition in the obstructive sleep apnea market

Which geography accounted for the largest Obstructive Sleep Apnea market size?

The United States accounted for the largest Obstructive Sleep Apnea market size.

What is the forecasted Obstructive Sleep Apnea market size in 2030?

DelveInsight estimates an increase in Obstructive Sleep Apnea Market Size during the study period, 2017-2030

What is the present Obstructive Sleep Apnea market drivers?

Upcoming pipeline, big data, and personalized therapy.

What is the Obstructive Sleep Apnea market barriers?

Economic cost, the efficacy of current treatment, and future competition are likely to block the market growth.

How many companies are developing drugs for Obstructive Sleep Apnea?

Many companies are working robustly in providing effective treatment to the individuals suffering from OSA like, Apnimed, Bayer, Idorsia, and others.

Which are the leading companies in the Obstructive Sleep Apnea market?

Key Players- Apnimed, Bayer, etc.

How is epidemiology segmented for Obstructive Sleep Apnea?

Diagnosed prevalent cases of OSA, Gender-specific cases of Obstructive Sleep Apnea, Age-specific cases of OSA, and Severity-specific cases of Obstructive Sleep Apnea.

Table of Contents

1 Key Insights

2 Executive Summary of Obstructive Sleep Apnea

3 SWOT Analysis for OSA

4 Obstructive Sleep Apnea Market Overview at a Glance

  • 4.1 Market Share (%) Distribution of Obstructive Sleep Apnea in 2017
  • 4.2 Market Share (%) Distribution of Obstructive Sleep Apnea in 2030

5 Disease Background and Overview

  • 5.1 Introduction
  • 5.2 Etiology
  • 5.3 Severity Based Classification
  • 5.4 Clinical Manifestations of Obstructive Sleep Apnea
  • 5.5 Symptoms
  • 5.6 Pathophysiology
  • 5.7 Risk factors
  • 5.8 Diagnosis

6 Epidemiology and Patient Population

  • 6.1 Key Findings

7 7MM Epidemiology

  • 7.1 Assumptions and rationale
  • 7.2 Total Diagnosed Prevalent cases of Obstructive Sleep Apnea (OSA) in 7MM
  • 7.3 United States
    • 7.3.1 Total Diagnosed Prevalent cases of Obstructive Sleep Apnea (OSA) in the United States
    • 7.3.2 Gender-Specific cases of Obstructive Sleep Apnea (OSA) in the United States
    • 7.3.3 Age-specific cases of Obstructive Sleep Apnea (OSA) in the United States
    • 7.3.4 Severity-specific cases of Obstructive Sleep Apnea (OSA) in the United States
  • 7.4 Germany
    • 7.4.1 Total Diagnosed Prevalent cases of Obstructive Sleep Apnea (OSA) in Germany
    • 7.4.2 Gender-specific cases of Obstructive Sleep Apnea (OSA) in Germany
    • 7.4.3 Age-specific cases of Obstructive Sleep Apnea (OSA) in Germany
    • 7.4.4 Severity-specific cases of Obstructive Sleep Apnea (OSA) in Germany
  • 7.5 France
    • 7.5.1 Total Diagnosed Prevalent cases of Obstructive Sleep Apnea (OSA) in France
    • 7.5.2 Gender-specific cases of Obstructive Sleep Apnea (OSA) in France
    • 7.5.3 Age-specific cases of Obstructive Sleep Apnea (OSA) in France
    • 7.5.4 Severity-specific cases of Obstructive Sleep Apnea (OSA) in France
  • 7.6 Italy
    • 7.6.1 Total Diagnosed Prevalent cases of Obstructive Sleep Apnea (OSA) in Italy
    • 7.6.2 Gender-specific cases of Obstructive Sleep Apnea (OSA) in Italy
    • 7.6.3 Age-specific cases of Obstructive Sleep Apnea (OSA) in Italy
    • 7.6.4 Severity-specific cases of Obstructive Sleep Apnea (OSA) in Italy
  • 7.7 Spain
    • 7.7.1 Total Diagnosed Prevalent cases of Obstructive Sleep Apnea (OSA) in Spain
    • 7.7.2 Gender-specific cases of Obstructive Sleep Apnea (OSA) in Spain
    • 7.7.3 Age-specific cases of Obstructive Sleep Apnea (OSA) in Spain
    • 7.7.4 Severity-specific cases of Obstructive Sleep Apnea (OSA) in Spain
  • 7.8 United Kingdom
    • 7.8.1 Total Diagnosed Prevalent cases of Obstructive Sleep Apnea (OSA) in the United Kingdom
    • 7.8.2 Gender-specific cases of Obstructive Sleep Apnea (OSA) in the United Kingdom
    • 7.8.3 Age-specific cases of Obstructive Sleep Apnea (OSA) in the United Kingdom
    • 7.8.4 Severity-specific cases of Obstructive Sleep Apnea (OSA) in the United Kingdom
  • 7.9 Japan
    • 7.9.1 Total Diagnosed Prevalent cases of Obstructive Sleep Apnea (OSA) in Japan
    • 7.9.2 Gender-specific cases of Obstructive Sleep Apnea (OSA) in Japan
    • 7.9.3 Age-specific cases of Obstructive Sleep Apnea (OSA) in Japan
    • 7.9.4 Severity-specific cases of Obstructive Sleep Apnea (OSA) in Japan

8 Treatment

9 Unmet Needs

10 Organizations contributing toward OSA

11 Case Study

  • 11.1 Case Study: Imaging of Apnea Termination in a Patient with Obstructive Sleep Apnea during Natural Sleep
  • 11.2 Treatment of Comorbid Obstructive Sleep Apnea by Upper Airway Stimulation Results in Resolution of Debilitating Symptoms of Restless Legs Syndrome
  • 11.3 Obstructive sleep apnea caused by acromegaly: A case report
  • 11.4 Case Study: Sleep Apnea Diagnosis in a Man with Type 2 Diabetes Improved Control

12 Patient Journey

13 KOL Views

14 Marketed Therapies

  • 14.1 Provigil: Teva Pharmaceuticals
    • 14.1.1 Product Description
    • 14.1.2 Other Development Activities
    • 14.1.3 Clinical Development
    • 14.1.4 Safety and Efficacy
  • 14.2 Nuvigil: Teva Pharmaceuticals
    • 14.2.1 Product Description
    • 14.2.2 Other Development Activities
    • 14.2.3 Clinical Development
    • 14.2.4 Safety and Efficacy
  • 14.3 Solriamfetol: Jazz Pharmaceuticals
    • 14.3.1 Product Description
    • 14.3.2 Other Developmental Activities
    • 14.3.3 Clinical Development
    • 14.3.4 Safety and Efficacy

15 Emerging Therapies

  • 15.1 Daridorexant: Idorsia Pharmaceuticals
    • 15.1.1 Product Description
    • 15.1.2 Other Development Activities
    • 15.1.3 Clinical Development
  • 15.2 BAY2586116: Bayer
    • 15.2.1 Product Description
    • 15.2.2 Clinical Development
  • 15.3 AD036: Apnimed
    • 15.3.1 Product Description
    • 15.3.2 Clinical Development
  • 15.4 AD128: Apnimed
    • 15.4.1 Product Description
    • 15.4.2 Clinical Development

16 Obstructive Sleep Apnea (OSA): Seven Major Market Analysis

  • 16.1 Key Findings
  • 16.2 Market Size of Obstructive Sleep Apnea (OSA) in 7MM

17 Seven Major Market Outlook

  • 17.1 The United States Market Size
    • 17.1.1 Total Market Size of Obstructive Sleep Apnea (OSA) in the United States
    • 17.1.2 Total Market Size of Obstructive Sleep Apnea (OSA) by Therapies in the United States
  • 17.2 Germany
    • 17.2.1 The total market size of Obstructive Sleep Apnea (OSA) in Germany
    • 17.2.2 Market size of Obstructive Sleep Apnea (OSA) by Therapies in Germany
  • 17.3 France
    • 17.3.1 The total market size of Obstructive Sleep Apnea (OSA) in France
    • 17.3.2 Market size of Obstructive Sleep Apnea (OSA) by Therapies in France
  • 17.4 Italy
    • 17.4.1 The total market size of Obstructive Sleep Apnea (OSA) in Italy
    • 17.4.2 Market size of Obstructive Sleep Apnea (OSA) by Therapies in Italy
  • 17.5 Spain
    • 17.5.1 Total Market Size of Obstructive Sleep Apnea (OSA) in Spain
    • 17.5.2 Market size of Obstructive Sleep Apnea (OSA) by Therapies in Spain
  • 17.6 United Kingdom
    • 17.6.1 The total market size of Obstructive Sleep Apnea (OSA) in the United Kingdom
    • 17.6.2 Market size of Obstructive Sleep Apnea (OSA) by Therapies in the UK
  • 17.7 Japan
    • 17.7.1 The total market size of Obstructive Sleep Apnea (OSA) in Japan
    • 17.7.2 Market size of Obstructive Sleep Apnea (OSA) by Therapies in Japan

18 Market Drivers

19 Market Barriers

20 Reimbursement

21 Appendix

  • 21.1 Report Methodology
  • 21.2 References

22 DelveInsight Capabilities

23 Disclaimer

24 About DelveInsight

List of Tables

  • Table 1: Summary of Obstructive Sleep Apnea Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: Total diagnosed prevalent cases of Obstructive Sleep Apnea (OSA) in 7MM (2017-2030)
  • Table 3: Total Diagnosed Prevalent cases of Obstructive Sleep Apnea (OSA) in the United States (2017-2030)
  • Table 4: Gender-specific cases of Obstructive Sleep Apnea (OSA) in the US (2017-2030)
  • Table 5: Age-specific cases of Obstructive Sleep Apnea (OSA) in the US (2017-2030)
  • Table 6: Severity-specific cases of Obstructive Sleep Apnea (OSA) in the US (2017-2030)
  • Table 7: Total Diagnosed Prevalent cases of Obstructive Sleep Apnea (OSA) in Germany (2017-2030)
  • Table 8: Gender-specific cases of Obstructive Sleep Apnea (OSA) in Germany (2017-2030)
  • Table 9: Age-specific cases of Obstructive Sleep Apnea (OSA) in Germany (2017-2030)
  • Table 10: Severity-specific cases of Obstructive Sleep Apnea (OSA) in Germany (2017-2030)
  • Table 11: Total Diagnosed Prevalent cases of Obstructive Sleep Apnea (OSA) in France (2017-2030)
  • Table 12: Gender-specific cases of Obstructive Sleep Apnea (OSA) in France (2017-2030)
  • Table 13: Age-specific cases of Obstructive Sleep Apnea (OSA) in France (2017-2030)
  • Table 14: Severity-specific cases of Obstructive Sleep Apnea (OSA) in France (2017-2030)
  • Table 15: Total Diagnosed Prevalent cases of Obstructive Sleep Apnea (OSA) in Italy (2017-2030)
  • Table 16: Gender-specific cases of Obstructive Sleep Apnea (OSA) in Italy (2017-2030)
  • Table 17: Age-specific cases of Obstructive Sleep Apnea (OSA) in Italy (2017-2030)
  • Table 18: Severity-specific cases of Obstructive Sleep Apnea (OSA) in Italy (2017-2030)
  • Table 19: Total Diagnosed Prevalent cases of Obstructive Sleep Apnea (OSA) in Spain (2017-2030)
  • Table 20: Gender-specific cases of Obstructive Sleep Apnea (OSA) in Spain (2017-2030)
  • Table 21: Age-specific cases of Obstructive Sleep Apnea (OSA) in the US (2017-2030)
  • Table 22: Severity-specific cases of Obstructive Sleep Apnea (OSA) in Spain (2017-2030)
  • Table 23: Total Diagnosed Prevalent cases of Obstructive Sleep Apnea (OSA) in the United Kingdom (2017-2030)
  • Table 24: Gender-specific cases of Obstructive Sleep Apnea (OSA) in the UK (2017-2030)
  • Table 25: Age-specific cases of Obstructive Sleep Apnea (OSA) in the UK (2017-2030)
  • Table 26: Severity-specific cases of Obstructive Sleep Apnea (OSA) in the UK (2017-2030)
  • Table 27: Total Diagnosed Prevalent cases of Obstructive Sleep Apnea (OSA) in Japan (2017-2030)
  • Table 28: Gender-specific cases of Obstructive Sleep Apnea (OSA) in Japan (2017-2030)
  • Table 29: Age-specific cases of Obstructive Sleep Apnea (OSA) in Japan (2017-2030)
  • Table 30: Severity-specific cases of Obstructive Sleep Apnea (OSA) in Japan (2017-2030)
  • Table 31: Components of Patient Education Programs
  • Table 32: OSA Symptoms that should be evaluated during a Comprehensive Sleep Evaluation
  • Table 33: Provigil, Clinical Trial Description, 2020
  • Table 34: Nuvigil, Clinical Trial Description, 2020
  • Table 35: Solriamfetol, Clinical Trial Description, 2020
  • Table 36: Daridorexant, Clinical Trial Description, 2020
  • Table 37: BAY2586116, Clinical Trial Description, 2020
  • Table 38: AD036, Clinical Trial Description, 2020
  • Table 39: AD128, Clinical Trial Description, 2020
  • Table 40: Market Size of Obstructive Sleep Apnea (OSA) in 7MM in USD Million (2017-2030)
  • Table 41: The US Market Size of Obstructive Sleep Apnea (OSA) in USD Million (2017-2030)
  • Table 42: US Market Size of Obstructive Sleep Apnea (OSA) in USD Million (2017-2030)
  • Table 43: Market Size of Obstructive Sleep Apnea (OSA) in Germany, USD Millions (2017-2030)
  • Table 44: Germany Market Size of Obstructive Sleep Apnea (OSA) by Therapies in USD Million (2017-2030)
  • Table 45: Market Size of Obstructive Sleep Apnea (OSA) associated in France, USD Millions (2017-2030)
  • Table 46: France Market Size of Obstructive Sleep Apnea (OSA) by Therapies in USD Million (2017-2030)
  • Table 47: Market Size of Obstructive Sleep Apnea (OSA) in Italy, USD Millions (2017-2030)
  • Table 48: Italy Market Size of Obstructive Sleep Apnea (OSA) by Therapies in USD Million (2017-2030)
  • Table 49: Market Size of Obstructive Sleep Apnea (OSA) in Spain, USD Millions (2017-2030)
  • Table 50: Spain Market Size of Obstructive Sleep Apnea (OSA) by Therapies in USD Million (2017-2030)
  • Table 51: Market Size of Obstructive Sleep Apnea (OSA) in the UK, USD Millions (2017-2030)
  • Table 52: UK Market Size of Obstructive Sleep Apnea (OSA) by Therapies in USD Million (2017-2030)
  • Table 53: Market Size of Obstructive Sleep Apnea (OSA) in Japan, USD Millions (2017-2030)
  • Table 54: Japan Market Size of Obstructive Sleep Apnea (OSA) by Therapies in USD Million (2017-2030)
  • Table 53: Market Size of Obstructive Sleep Apnea (OSA) in Japan, USD Millions (2017-2030)
  • Table 54: Japan Market Size of Obstructive Sleep Apnea (OSA) by Therapies in USD Million (2017-2030)

List of Figures

  • Figure 1: Pathological relationship between sleep apnea and cardiovascular disease
  • Figure 2: Schematic representation of the typical pathophysiological sequence in obstructive sleep apnea (OSA).
  • Figure 3: Schematic representation of the possible sites where each of the various pathophysiological traits would either predispose or tend to worsen OSA
  • Figure 4: A diagram to illustrate the risk factors for OSA
  • Figure 5: Clinical algorithm for implementation of clinical practice guidelines
  • Figure 6: Total diagnosed prevalent cases of Obstructive Sleep Apnea (OSA) in 7MM (2017-2030)
  • Figure 7: Total Diagnosed Prevalent Cases of OSA in the United States (2017-2030)
  • Figure 8: Gender-Specific cases of Obstructive Sleep Apnea (OSA) in the US (2017-2030)
  • Figure 9: Age-specific cases of Obstructive Sleep Apnea (OSA) in the US (2017-2030)
  • Figure 10: Severity-specific cases of Obstructive Sleep Apnea (OSA) in the US (2017-2030)
  • Figure 11: Total Diagnosed Prevalent cases of Obstructive Sleep Apnea (OSA) in Germany (2017-2030)
  • Figure 12: Gender-specific cases of Obstructive Sleep Apnea (OSA) in Germany (2017-2030)
  • Figure 13: Age-specific cases of Obstructive Sleep Apnea (OSA) in Germany (2017-2030)
  • Figure 14: Severity-specific cases of Obstructive Sleep Apnea (OSA) in Germany (2017-2030)
  • Figure 15: Total diagnosed Prevalent cases of Obstructive Sleep Apnea (OSA) in France (2017-2030)
  • Figure 16: Gender-specific cases of Obstructive Sleep Apnea (OSA) in France (2017-2030)
  • Figure 17: Age-specific cases of Obstructive Sleep Apnea (OSA) in France (2017-2030)
  • Figure 18: Severity-specific cases of Obstructive Sleep Apnea (OSA) in France (2017-2030)
  • Figure 19: Total Diagnosed Prevalent cases of Obstructive Sleep Apnea (OSA) in Italy (2017-2030)
  • Figure 20: Gender-specific cases of Obstructive Sleep Apnea (OSA) in Italy (2017-2030)
  • Figure 21: Age-specific cases of Obstructive Sleep Apnea (OSA) in Italy (2017-2030)
  • Figure 22: Severity-specific cases of Obstructive Sleep Apnea (OSA) in Italy (2017-2030)
  • Figure 23: Total Diagnosed Prevalent cases of Obstructive Sleep Apnea (OSA) in Spain (2017-2030)
  • Figure 24: Gender-specific cases of Obstructive Sleep Apnea (OSA) in Spain (2017-2030)
  • Figure 25: Age-specific cases of Obstructive Sleep Apnea (OSA) in Spain (2017-2030)
  • Figure 26: Severity-specific cases of Obstructive Sleep Apnea (OSA) in Spain (2017-2030)
  • Figure 27: Total Diagnosed Prevalent cases of Obstructive Sleep Apnea (OSA) in the UK (2017-2030)
  • Figure 28: Gender-specific cases of Obstructive Sleep Apnea (OSA) in the UK (2017-2030)
  • Figure 29: Age-specific cases of Obstructive Sleep Apnea (OSA) in the UK (2017-2030)
  • Figure 30: Severity-specific cases of Obstructive Sleep Apnea (OSA) in the UK (2017-2030)
  • Figure 31: Total Diagnosed Prevalent cases of Obstructive Sleep Apnea (OSA) in Japan (2017-2030)
  • Figure 32: Gender-specific cases of Obstructive Sleep Apnea (OSA) in Japan (2017-2030)
  • Figure 33: Age-specific cases of Obstructive Sleep Apnea (OSA) in Japan (2017-2030)
  • Figure 34: Severity-specific cases of Obstructive Sleep Apnea (OSA) in Japan (2017-2030)
  • Figure 35: CPAP Treatment. Approach to the initiation, management, and follow-up of CPAP.
  • Figure 36: Behavioral Treatment. Approach to the initiation, management, and follow-up of behavioral treatment.
  • Figure 37: Surgical Treatment. Approach to the management of OSA with surgical therapy.
  • Figure 38: Adjunctive Treatment. Approach to the management of OSA with adjunctive therapies
  • Figure 39: Unmet Needs of OSA
  • Figure 40: Market Size of Obstructive Sleep Apnea (OSA) in USD Million (2017-2030)
  • Figure 41: Market Size of Obstructive Sleep Apnea (OSA) in the US, USD Millions (2017-2030)
  • Figure 42: Market Size of Obstructive Sleep Apnea (OSA) in the US by therapies, USD Millions (2017-2030)
  • Figure 43: Market Size of Obstructive Sleep Apnea (OSA) in Germany, USD Millions (2017-2030)
  • Figure 44: Market Size of Obstructive Sleep Apnea (OSA) in Germany by therapies, USD Millions (2017-2030)
  • Figure 45: Market Size of Obstructive Sleep Apnea (OSA) in France, USD Millions (2017-2030)
  • Figure 46: Market Size of Obstructive Sleep Apnea (OSA) in France by therapies, USD Millions (2017-2030)
  • Figure 47: Market Size of Obstructive Sleep Apnea (OSA) in Italy, USD Millions (2017-2030)
  • Figure 48: Market Size of Obstructive Sleep Apnea (OSA) in Italy by therapies, USD Millions (2017-2030)
  • Figure 49: Market Size of Obstructive Sleep Apnea (OSA) in Spain, USD Millions (2017-2030)
  • Figure 50: Market Size of Obstructive Sleep Apnea (OSA) in Spain by therapies, USD Millions (2017-2030)
  • Figure 51: Market Size of Obstructive Sleep Apnea (OSA) in the UK, USD Millions (2017-2030)
  • Figure 52: Market Size of Obstructive Sleep Apnea (OSA) in the UK by therapies, USD Millions (2017-2030)
  • Figure 53: Market Size of Obstructive Sleep Apnea (OSA) in Japan, USD Millions (2017-2030)
  • Figure 54: Market Size of Obstructive Sleep Apnea (OSA) in Japan by therapies, USD Millions (2017-2030)
  • Figure 55: Market Drivers
  • Figure 56: Market Barriers